Today's Rundown Gilead, Galapagos’ filgotinib hits goals in phase 2, but DVT case gives investors a scare Third Rock’s Rheos poaches Sanjay Keswani from Roche Inscripta picks up Solana to commercialize gene-editing tools SpringWorks names a CEO, inks a combo therapy deal with BeiGene 4D raises $90M to move gene therapies into clinical testing with AstraZeneca and Roche Xenon adds discontinued GlaxoSmithKline drug ezogabine to epilepsy pipeline Allogene raises another $120M for off-the-shelf CAR-T programs 28-7 Therapeutics raises $65M for cancer drugs aimed at tumor-suppressing RNA Featured Story | | | Thursday, September 6, 2018 A phase 2 trial of Gilead and Galapagos’ JAK1 inhibitor filgotinib has met its primary endpoint. The results position the potential blockbuster to advance into phase 3 in ankylosing spondylitis, although a safety signal gave investors a scare. |
|
|
| This week's sponsor is Trianni. | | | |
Top Stories Thursday, September 6, 2018 Third Rock Ventures’ Rheos Medicines has named former Roche SVP Sanjay Keswani, M.D., as CEO. The appointment puts Keswani in charge of overseeing Rheos’ pipeline of immunometabolism assets. Wednesday, September 5, 2018 Inscripta will acquire Solana Biosciences to ramp up the commercialization of its gene-editing technology. The Boulder, Colorado-based biotech aims to broaden access to CRISPR by offering new enzymes for free, and to boost CRISPR research by outfitting scientists with a full suite of tools. Thursday, September 6, 2018 A year after launching, SpringWorks Therapeutics has named its first CEO and unveiled a partnership with BeiGene that focuses on a targeted combination therapy for RAS-mutated cancers. Wednesday, September 5, 2018 4D Molecular Therapeutics raised $90 million in venture capital funding and plans to advance its AAV vector platform and treatments into clinical trials through collaborations with AstraZeneca's MedImmune and Roche. Thursday, September 6, 2018 Xenon Pharmaceuticals is taking a stab at repurposing GlaxoSmithKline's ezogabine for a rare, difficult-to-treat form of pediatric epilepsy caused by a genetic mutation. Thursday, September 6, 2018 Allogene’s bustling first few months have continued with a $120 million private financing round that will help it advance its off-the-shelf CAR-T therapies for cancer. Thursday, September 6, 2018 28-7 Therapeutics has launched with $65 million to fund its cancer treatments, which aim to increase the levels of tumor-suppressing RNA genes, using Harvard tech and backed by Novartis’ VC arm. | This week's sponsor is ExL Events. | | Discount price rate ends 9/7 for the Collaborations Addressing Vulnerable Populations (CAVP) Forum!
The CAVP Forum is a four-track, two-day event designed for organizations that support the discovery and development of treatments for underserved and neglected patient populations. View the full agenda today! —Save 15% with code C1069FIERCE |
Resources Sponsored by: Patheon, part of Thermo Fisher Scientific When developing a parenteral, pharmaceutical scientists are faced with a variety of choices – choices that can be conflicting or present differing advantages. Sponsored by: Baxter Baxter BioPharma Solutions’ whitepaper offers a method to address the challenges of tech transfer for lyophilized products from lab-scale to commercial-scale. Sponsored by: Blue Matter A whitepaper outlining the key commercial challenges facing rare disease products, and how biopharmaceutical companies can overcome them. Sponsored by: Catalent In this case study, an unknown leachable species was detected by GC-MS analysis of an alkaline drug product (pH approximately 10.5) that was packaged in a novel self- contained plastic Blow Fill Seal (BFS) vial. Sponsored by: AWS and Tableau Inova is using the capabilities of Tableau on AWS to identify biomarkers for personalized treatment intended to improve health outcomes for children. Sponsored by: AWS and Reltio Reltio and IQVIA provide holistic data management solutions for traditional pharma, emerging biotech, and consumer health companies, on AWS. Sponsored by: Catalent Catalent provides world class stability services to ease your critical path to success. Presented by: AWS and Druva Life Sciences organizations are embracing cloud-based Master Data Management (MDM) to modernize the organization of critical data. Sponsored by: Health Strategies Group The window of market exclusivity continues to narrow dramatically in the global marketplace. Given this demanding environment, your global market access team faces increasing urgency to get the value proposition right at the time of launch. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: PharmaCord When was the last time your patient support program perfectly aligned with the patient journey, solving all the critical gaps in positioning your brand for success? Follow the 3-D approach to your solution design, and you will achieve a better outcome for your patients. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. Drug Approval, Manufacturing Quality & Regulation 2018 | Online RESI HealthTech Week September 5-7, 2018 | Boston, MA 2018 Latin America Healthcare Compliance Certification Program September 24-27, 2018 | Sao Paulo, Brazil Drug Development Immersion September 26-27, 2018 | West Windsor, NJ FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA Compliance Certification Program at Seton Hall Law October 8-11, 2018 | Newark, NJ BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL Fierce Innovation Awards: Life Sciences Edition 2018 FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Understanding Commercialization Within Biopharma Nov 7-8, 2018 | Boston, MA Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation Drug Development Immersion December 5-6, 2018 | San Diego, CA Understanding Drug Pricing and Reimbursement December 12, 2018 | Boston, MA | 